Sage Therapeutics (SAGE) Upcoming Ph2 Data Could Add $8 to the Share Price - SVB Leerink
Tweet Send to a Friend
SVB Leerink analyst Marc Goodman reiterated a Market Perform rating and $45.00 price target on Sage Therapeutics (NASDAQ: SAGE) ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
